Close this search box.

J&J adds bispecific for atopic dermatitis via deal with Numab


Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal

By Paul Bonanos, Director of Biopharma Intelligence

May 28, 2024 9:19 PM UTC

Less than two weeks after J&J acquired Proteologix for its dual-action antibody to treat immunological disorders, the pharma has reached another billion-dollar deal with Numab to give it another bispecific in the same disease area.

Johnson & Johnson (NYSE:JNJ) is paying $1.25 billion for rights to NM26, a Phase II-ready asset targeting IL-4RA and IL-31, through the acquisition of Numab Therapeutics AG subsidiary Yellow Jersey Therapeutics…